Scientists are trying to help the brain replace lost dopamine in people with Parkinson's. Will gene therapy or cell replacement work eventually?
On September 22 in New York City, the <a href="http://www.aging-institute.org/">Institute for the Study of Aging</a> hosted a conference to assess...
Alzheimer Disease, Aging, and the Immune System Synaptic Function in Aging and AD High-throughput Assays (Application of OMICS to AD) Recommendations for Future Research Enabling Technologies for Alzheimer Disease Research: 2006 Bar Harbor Workshop ...
In narrower claim, the drug is said to promote ApoE lipidation only in brain regions with extensive amyloid in mice carrying human ApoE4.
Researchers have partnered with Google-funded Calico Life Sciences to develop a molecule that protects neurons in a variety of conditions.
The ALS Ice Bucket Challenge has yielded more than $100 million—what research projects should get a share of the action?
Novartis Pharmaceuticals Corporation will partner with the Banner Alzheimer's Institute testing experimental preclinical therapies in the upcoming Alzheimer's Prevention Initiative ApoE4 study. The study complements the API ADAD trial.
When strict quality control standards are followed, low Aβ in cerebrospinal fluid accurately predicts amyloid plaques in people with cognitive impairment in clinical practice.
Scientists report a case of identical twins with the C9ORF72 DNA expansion—only one has ALS.
Supplements of resveratrol, a compound found in red grapes and wine, improved memory, metabolism, and brain connectivity in a group of overweight older adults.
A mouse study testing the combined effects of a BACE inhibitor and plaque-clearing antibody builds new support for a combination strategy aimed at reducing Aβ buildup in people.
An active immunotherapy is coming to the fore as researchers continue to try novel therapies.
Does a tau-based early diagnosis look more likely?
Blocking the microglial receptor for pro-inflammatory prostaglandin D2 protects motor neurons from glial toxicity in ALS cell and mouse models.
Protein oligomers may be to blame in TDP-43 proteinopathies, as in other neurodegenerative conditions.
No filters selected